<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111445</url>
  </required_header>
  <id_info>
    <org_study_id>ADG116-1001</org_study_id>
    <nct_id>NCT04111445</nct_id>
  </id_info>
  <brief_title>Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors</brief_title>
  <official_title>First-in-human (FIH), Open-Label, Phase I (Dose Escalation) Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagene Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagene Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with&#xD;
      advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human&#xD;
      monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered&#xD;
      intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study discontinued due to business decision.&#xD;
  </why_stopped>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Actual">April 27, 2021</completion_date>
  <primary_completion_date type="Actual">April 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities</measure>
    <time_frame>From first dose of ADG116 (Week 1 Day 1) until 30days after the last ADG116 injection (up to 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>From first dose of ADG116 (Week 1 Day 1) until 30days after the last ADG116 injection (up to 2 years)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ADG116</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADG116</intervention_name>
    <description>IV infusion at Day 1 of each cycle</description>
    <arm_group_label>ADG116</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Male or female, 18-75 years of age at the time of consent.&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
          -  Subjects with advanced and/or metastatic histologically or cytologically confirmed&#xD;
             solid tumor who have not responded or progressed after standard therapies or for whom&#xD;
             no further standard therapy exists or standard therapy is not available&#xD;
&#xD;
          -  Patients who are refractory or relapsed to prior anti-CTLA4 checkpoint inhibitors will&#xD;
             also be recruited if they meet all eligibility criteria.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2.&#xD;
&#xD;
          -  Adequate organ and bone marrow function&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             within the 7 days prior to study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  Treatment with any investigational drug within 4 weeks prior to the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Grade ≥ 3 immune-related adverse events (irAE) or irAE that lead to discontinuation of&#xD;
             prior immunotherapy. Untreated or uncontrolled central nervous system (CNS) tumors or&#xD;
             metastases&#xD;
&#xD;
          -  Any active autoimmune disease or documented history of autoimmune disease.&#xD;
&#xD;
          -  Infection of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis&#xD;
             C virus (HCV)&#xD;
&#xD;
          -  Subjects requiring systemic treatment with corticosteroids or other immunosuppressive&#xD;
             medications within 21 days before the planned first dose of study drug.&#xD;
&#xD;
          -  Current or prior history of pneumonitis, hepatitis, nephritis, colitis or thyroiditis.&#xD;
             Peripheral neuropathy ≥ Grade 2.&#xD;
&#xD;
          -  History of clinically significant cardiac disease.&#xD;
&#xD;
          -  Uncontrolled current illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

